GAO: FDA yet to make safety changes post-Vioxx
The Food and Drug Administration still hasn’t restructured its staff to better monitor drug safety, more than three years after experts recommended key changes in the wake of the Vioxx scandal.
December 9, 2009
Margaret McGlynn, critical to a post-Vioxx turnaround, is on a fast track
Vioxx Successor Arcoxia May Have Similar Heart Attack Risks
Arcoxia, a new experimental painkiller Merck & Co hope will become the successor of Vioxx, which was taken off the market because of its heart attack risks, may have similar risks, say scientists who looked at 23 clinical trials comparing several painkillers.You can read about this new report in JAMA (the Journal of the American Medical Association). [click link for full article]
Jurors in Vioxx trial begin deliberating
Jurors in the seventh trial over withdrawn painkiller Vioxx began deliberating this morning over the plaintiff's claim that the former Merck & Co. drug caused her 2004 heart attack. Lawyers for Elaine Doherty, a 68-year-old grandmother of seven from Lawrenceville, alleged during the 5-week trial that Vioxx was a major cause of her heart attack and that Whitehouse Station-based Merck downplayed
